⌘K

Login Start Free

Home/Filings/5/0001140361-11-012555

5//SEC Filing

NEVO DORON 5

Accession 0001140361-11-012555

CIK 0001451980other

View on SEC.gov Company Profile

Filed

Feb 27, 7:00 PM ET

Accepted

Feb 28, 2:11 PM ET

Size

10.6 KB

Accession

0001140361-11-012555

Insider Transaction Report

Form 5

Period: 2010-12-31

BIOCANCELL THERAPEUTICS INC.BICL.TA

Director

Transactions

Purchase
Series 3 Warrants
2010-11-23+100,000→ 100,000 total
Exp: 2012-11-17→ Common Stock (100,000 underlying)
Purchase
Series 4 Warrants
2010-12-01+50,000→ 99,995 total
Exp: 2014-11-17→ Common Stock (50,000 underlying)
Purchase
Series 4 Warrants
2010-12-02+49,995→ 99,995 total
Exp: 2014-11-17→ Common Stock (49,995 underlying)

Footnotes (6)

[F1]The exercise price of Series 3 Warrants is 3.69 NIS per share.
[F2]The warrants are exercisable at any time until their expiration.
[F3]The average purchase price was 0.57 NIS per warrant.
[F4]The exercise price of Series 4 Warrants is 4.43 NIS per share.
[F5]The average purchase price was 0.60 NIS per warrant.
[F6]The average purchase price was 0.57 NIS per warrant.

Documents

1 file

5
doc1.xmlPrimary
FORM 5

Issuer

BIOCANCELL THERAPEUTICS INC.

CIK 0001451980

Entity typeother

Related Parties

1

filerCIK 0001286028

Filing Metadata

Form type: 5
Filed: Feb 27, 7:00 PM ET
Accepted: Feb 28, 2:11 PM ET
Size: 10.6 KB

View on SEC.gov